Getinge – Passion for Life

Investor Relations Deck

July 2026

GETINGE

Content

1. Equity story
2. Introduction to Getinge
3. Latest Capital Market Update (Extract)
4. Latest Quarterly Report (Extract)

Equity story

World-leading Medtech at an inflection point

Quality cost release beginning H2 2026, the operational inflection is visible

WHO WE ARE

#1-2 positions in core categories

- SEK ~35 B revenue, 67% recurring
- SEK 200 B addressable market growing 4-6% per year
- Sole or dual-source supplier in several critical customer categories
- Quality resolution on track – 53% reduction in field actions KPI[1]

#1-2 positions

30,000 customers

135 countries

INVESTMENT CASE

Visible margin recovery

Underlying improvement masked in 2025 by SEK ~1 B tariff & FX headwind[2]

Adj. EBITA margin (%)



Near-term
Significant quality cost release
~Gradually from H2 2026 to 2028

Ongoing
Mix shift to recurring
From 61% to 67% since 2023

Ongoing
Productivity gains & innovation
Share of high margin products at 70%

SHAREHOLDER RETURN

Prioritised dividend and healthy leverage

>12%
Adj. EPS CAGR
Financial target 2024-2028[3]

30-50% of net profit
Seven consecutive years of dividend growth
Dividend policy

1.7x[4]
Significant headroom vs. 2.5x threshold
Net debt to adj. EBITDA in Q2 2026

[1] Reduction in Field Actions per Bn SEK net sales since 2023; [2] Majority of paid tariffs were refunded in Q2 2026 (36 MUSD); [3] Base year 2023; [4] 1.3x excluding pensions

GETINGE

Introduction to Getinge

We make life-saving technology accessible for more people

Key facts



1904

Founded in Getinge, Sweden

35
BSEK

Net sales 2025

85%

85% of sales go to hospitals, 15% to pharma & research

Approx. 30,000

Customers in >135 countries

Gothenburg

HQ located in Sweden

Approx.12,000

Co-workers worldwide

GETINGE

Top 10 markets

Representing about 75% of total sales in 2025



Making a difference

All people and societies need access to best possible care

18 million people die each year from cardiovascular diseases, making it the number 1 cause of death globally.*

Hundreds of millions of people are affected by health care acquired infections (HAI) each year.*

In the U.S. alone, more than 100,000 people are waiting for lifesaving organ transplants.

* www.who.int

GETINGE

Empowering our customers with knowledge, technology and resources



We are working together with our customers within five areas to improve clinical and economic results

Intensive Care

Aiming to improve clinical outcomes and reduce length of stay

Innovative and sustainable life supporting solutions for patients with acute medical conditions, post-operative patients and for neonates.

Offering include:

- ICU & NICU ventilation
- Extracorporeal life support
- Advanced monitoring
- Intra-aortic counterpulsation
- Transplant care
- Pendants
- Device Lifecycle Management

GETINGE

Cardiovascular Procedures

Therapies supporting faster recoveries and less risk of complications

Cardiovascular therapies and solutions that aim to enable more effective interventions, where patients experience better outcomes and faster recovery, today and in the future.

Offering include:

- Covered stents
- Vascular grafts
- Intra-aortic counter pulsation
- Anesthesia machines
- Endoscopic vessel harvesting
- Beating heart surgery
- Thoracic drainage
- Device lifecycle management

Operating Rooms

Bringing the most out of the operating room

Therapies and equipment ensuring that surgical procedures go according to plan for everyone involved, and that operating rooms are consistently used to its full capacity.

Offering include:

- Architectural planning and service solutions
- Operating tables
- Operating lights
- Anesthesia machines
- Digital OR solutions for integration & management
- Ceiling supply units
- Device Lifecycle Management

GETINGE

Sterile Reprocessing

Enabling sterilized surgical instruments on time, for each procedure

Optimizing sterile reprocessing is about timing and control,
to prevent infections and keep surgical procedures on time.

Offering include:

- Sterilizers
- Washer-disinfectors
- Low-temp sterilization
- Consumables
- Sterile supply management solutions
- Endoscopy equipment
- Workflow offering
- Architectural planning and service solutions
- Device lifecycle management

GETINGE

Life Science

Preventing contamination in research and production

From research laboratories to pharmaceutical production, we support every step of your journey. With focus on contamination prevention and upstream bioprocessing, we provide tailored solutions to scientists and engineers who are dedicated to preventing, mitigating and curing diseases.

Offering include:

- Bioreactor systems
- Aseptic transfer systems
- CGMP washers and sterilizers
- Lab washers and sterilizers
- Isolators
- Closure processing systems
- Device Lifecycle Management

Digital Health Solutions

Digital Health Solutions

Simplifying life for hospital staff

Contributing to better working conditions while optimizing workflows through advanced technology (e.g., AI, BI, Automation) and connected devices/equipment.

INSIGHT Patient Flow Management
Healthcare. In harmony.

Tegris OR Integration
Crystal-clear vision

Torin OR Management
Your sixth sense

T-DOC Sterile Supply Management
360-degree perception. To the smallest detail.

GETINGE

Sustainability

Sustainability is an integral part of our strategy as we want to shape a future where healthcare is better, efficient and accessible.

‘Quality and Responsible Business’ together with ‘Engaged Employees’ form the backbone of the sustainability approach. ‘Sustainable innovations for better health’ is the driving force and leads the way to spearhead Getinge’s sustainability work.

Committed to net zero emissions by 2050

Science Based Targets initiative (SBTi) approved

2021

Base year

2030

>90% reduction of all scope 1 & 2 emissions*

25% reduction scope 3**

2050

Net zero***



(Reduction of emissions excluding offsetting)

* All scope 1 & 2 emissions including leased assets (company vehicles), other greenhouse gases such as anesthesia used in production and energy used in non-production premises such as office buildings

** Reduction vs. baseline 2021

*** Net zero means reducing our (scope 1, 2 & 3) emissions by >90% in 2050 vs baseline 2021 and balance remaining 10% by removals

GETINGE

Where our solutions come to life

Production sites around the world

23 production sites in 9 countries

United States
Englewood, Mahwah, Merrimack, Wayne, Fraser, Smithfield

Germany
Hechingen, Rastatt, Feldkirchen

France
Ardon, La Ciotat, Tournefeuille, Vendôme, Grenoble, Bobigny

Sweden
Solna, Växjö, Getinge

Poland
Poznan

Turkey
Antalya

United Kingdom
Derby

The Netherlands
Delft

China
Suzhou

GETINGE

Our history

This is Getinge

Making life-saving technology accessible for more people



Our organization

Approx. 12,000 co-workers

of which...

- **1,000** work in Research & Development
- **1,500** work with field sales
- **1,900** work with field service
- **2,800** work in production
- **4,700** work in supporting functions

Our organization



Getinge Executive Team

Mattias Perjos
President & CEO

Magnus Lundbäck
EVP
Human Resources

Joanna Engelke
EVP
Quality Compliance, Regulatory & Medical Affairs

Anna Romberg
EVP
Sustainability, Legal & Compliance

Agneta Palmér
Chief Financial Officer

Alexandra Holland
EVP
Communications

Carsten Blecker
Chief
Commercial Officer

Elin Frostehav
President
Acute Care Therapies

Stéphane Le Roy
President
Surgical Workflows

Eric Honroth
President
Life Science

Extract - Latest Capital Market Update

May 2024

Getinge’s expected growth as normalization takes place
2024-2028

Projected organic growth in net sales 2024-2028

- 3-6%

Key factors in projection

- Negative financial impact from Cardiopulmonary and Cardiac Assist
- Normalization in mix towards high margin products in Life Science and Surgical Workflows
- Inflation continuing to normalize
- China’s expected growth expected to still be strong, but rather high single digits than mid-teens
- Productivity focus (Quality Value engineering, Portfolio pruning, Consolidation of supplier base etc.)

Additional growth potential from acquisitions

- Selective areas – strategic fit and appropriate risk profile
- Financial restrictions: aim to be below 2.5x Net Debt/EBITDA

Acute Care Therapies

Challenges still impacting – expecting continued negative effects

Projected organic growth in net sales 2024-2028

- 3-5%

Key factors in projection

- Product challenges in Cardiac Assist and Cardiopulmonary in US impacting negatively in 2024-2028 (as presented previously)
- Consolidation in ventilator market
- US and China remain our two largest markets
- New product launches from successful innovation and indication/therapy expansions

In addition: potential growth from acquisitions

- Focus on Acute Heart & Lung Support segment







Growth projection assumes current quality challenges are solved according to plan and no new major issues evolve from ongoing remediation and launches of related hardware

Life Science

Biopharma segment expected to bottom out in 2024-2025

Projected organic growth in net sales 2024-2028

- 6-10%

Key factors in projection

- Low to mid-teen growth in Biopharma
- GLP-1 supporting healthy capital goods business
- Uncertainty when it comes to China
- Continued partnerships with key Biopharma companies and their expansion plans

In addition: potential growth from acquisitions

- Focus on Bioprocessing, mainly US







Surgical Workflows

Main growth opportunities in consumables, new segments and digital solutions

Projected organic growth in net sales 2024-2028

- 4-6%

Key factors in projection

- Low single digit growth in core capital equipment and service segments
- Double digit growth expected in digital solutions and IC consumables from acquisitions and increased presence in new segments (low temp sterilization and endoscopy reprocessing)
- Growing exposure to the US market, headwinds expected in China

In addition: potential growth from acquisitions

- Opportunistic tuck-in acquisitions in Consumables & Digital







Financial target and dividend policy for 2024-2028

>12%

Adjusted EPS, CAGR

Base year: 2023. Assumptions: average organic net sales growth of 3-6% and adj. EBITA margin in line with the structurally motivated margin of ~16-19% by 2028.

30-50%

Dividend of Net Profit

GETINGE

Updated sustainability targets

Based on a double materiality analysis – relevant priorities integrated in the Corporate Strategy

Social

- Employee engagement: >70%
- Quality regulatory compliance, audit findings per inspection: <1.5 findings

Environment

- Reduce Scope 1 and 2 emissions by 90% by 2030*
- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050*

Governance

- Percentage of employees who completed training in business ethics: >90%

*Base year 2021

Productivity improvements ahead

Continuous improvements within the structure – healthy support to margins



Portfolio pruning

Quality Value Engineering

Consolidation of suppliers

Effective processes in purchasing, production, logistics, sales, quality and service

Potential structural cost adjustments paced with progress in Cardiopulmonary and Cardiac Assist

GETINGE

Getinge's structurally motivated EBITA margin
2024-2028



Extract – Latest Quarterly Report

Q2 2026

Healthy organic growth, high profitability and strong cash flow

Getinge Q2 2026

Mattias Perjos, CEO
Agneta Palmér, CFO

Key pillars for Getinge's profitable growth journey

Development for strategic KPIs

Increase share from recurring revenue



Increase sales share from high margin products[1]



Less field actions per Bn SEK Net sales



Improvements should be achieved through balanced leverage[2] and attractive long-term Return on Invested Capital[3]

Sales share in R12 figures. [1] Defined as products with adjusted gross margin higher than its Business Area in 2024; [2] Net debt/adj. EBITDA < 2.5; [3] ROIC at least > Weighted Average Cost of Capital

Key takeaways
Q2 2026

- Net sales grew by 4.6% organically and order intake increased by 6.2% organically
- Healthy margins in the quarter - impacted by both tariff refund and underlying solid improvement
- Strong cash flow and financial position







Key activities and events
Q2 2026

Offering and Customers

- Strong product launches:
  - Aquadis Endo 110 (Automated endoscope reprocessing)
  - Fluobeam LS (Fluorescence imaging)
  - Vasoview Hemopro 3, (Endoscopic Vessel Harvesting)
- Digital OR Innovation Center opened in Hamburg
- Acquisition of Pennamed, UK-based distributor of endoscopic consumables
- Middle East: So far limited impact on topline and cost

Sustainability, Quality and other

- 510(k) application submitted end of Q2 for Cardiosave (Intra-Aortic Balloon Pump)
- Product quality KPI continues to improve
- Scope 1 and 2 GHG emissions reduced by more than -15% year on year
- IEEPA tariff refund of approximately 36 MUSD

Fluobeam LS

Aquadis Endo 110

Vasoview Hemopro 3

Healthy organic topline growth – especially in Acute Care Therapies

Order Intake and Net Sales Bridge Q2 2025 – Q2 2026

Order Intake



Net Sales



Margins strengthened by tariff refund and underlying improvements

Adjusted Gross Profit and EBITA Bridge Q2 2025 – Q2 2026

Adjusted Gross Profit

Adj GM,%				
Q2 2026	65.0	40.4	45.5	55.4
(Q2 2025)	(58.0)	(38.6)	(43.6)	(50.8)



Gross Margin impact

Product and Geo mix ↑ Price ↑

Cost (incl. tariffs) ↓ Currency ↓

Adjusted EBITA

Margin development

+4.8 pp	Adj GP
+1.1 pp	Adj OPEX
+0.2 pp	D&A
-0.4 pp	FX



Getinge continues to have a solid financial position

Strong FCF in quarter and good safety margin on leverage

FCF positively impacted by improved operating profit…



… and leverage continues to be well below 2.5x



Steady traction towards mid-term guidance span

Halfway to end of 2028 and 0.8 pp remaining to span



Outlook 2026

Net sales for 2026 expected to increase by 3-5% organically*



* Adjusted for the phase-out of Surgical Perfusion, which is expected to have net sales in 2026 declining from about 250 MSEK to 50 MSEK

GETINGE

PASSION FOR LIFE